| Literature DB >> 35020786 |
Brendan Fitzgerald1, Keelin O'Donoghue2,3, Noel McEntagart4, John E Gillan5, Peter Kelehan5, John O'Leary6, Paul Downey7, Jonathan Dean8, Cillian F De Gascun8, John Bermingham9, Fionnvola Armstrong10, Attia Al Fathil11, Nicola Maher12, Cliona Murphy13, Louise Burke1,14.
Abstract
CONTEXT.—: A severe third wave of COVID-19 disease affected Ireland in the first 3 months of 2021. In this wave, 1 second-trimester miscarriage and 6 stillbirths were observed in the Irish population because of placental insufficiency as a result of SARS-CoV-2 placentitis. This observation was at odds with the country's previous experience with COVID-19 disease in pregnant mothers. OBJECTIVE.—: To describe the clinical and pathologic features of these pregnancy losses. DESIGN.—: Retrospective review of clinical and pathologic data of cases of second-trimester miscarriage, stillbirth, or neonatal death identified by perinatal pathologists as being due to SARS-CoV-2 placentitis during the third wave of COVID-19 in Ireland. RESULTS.—: Clinical and pathologic data were available for review in 6 pregnancies. Sequencing or genotyping of the virus identified SARS-CoV-2 alpha (B.1.1.7) in all cases. Three of the 6 cases had maternal thrombocytopenia, and fetal growth restriction was not prominent, suggesting a rapidly progressive placental disease. CONCLUSIONS.—: The identification of SARS-CoV-2 alpha in all these cases suggests that the emergence of the variant was associated with an increased risk of fetal death due to SARS-CoV-2 placentitis when compared with the original virus. Maternal thrombocytopenia may have potential as a clinical marker of placentitis, but other inflammatory markers need investigation. Three of the 6 women had been assessed for reduced fetal movements in hospital some days before the fetal deaths actually occurred; this could suggest that there may be a window for intervention in some cases.Entities:
Mesh:
Year: 2022 PMID: 35020786 DOI: 10.5858/arpa.2021-0586-SA
Source DB: PubMed Journal: Arch Pathol Lab Med ISSN: 0003-9985 Impact factor: 5.534